Thomas Gad founded Y-mAbs Therapeutics in April 2015 and has been a member of the Board of Directors since the Company’s inception. Mr. Gad serves as Founder, Vice Chairman of the Board of Directors, and Chief Business Officer. Inspired by his daughter’s transformational and challenging journey
Bo Kruse serves as Chief Financial Officer, Treasurer, and Secretary of the Company. Mr. Kruse has broad international finance experience, including knowledge of capital markets, accounting, and other financing activities. Prior to joining the Company, Mr.
Norman LaFrance, M.D., joined Y-mAbs as Chief Development Officer in June 2024. Dr. LaFrance brings over 40 years of deep radiopharmaceutical experience as both a nuclear medicine physician and pharmaceutical executive. He previously served as Chief Medical Officer, Senior Vice President of PLUS
Torben Lund-Hansen, PhD, serves as SVP, Chief Technical Officer. Dr. Lund-Hansen has substantial experience in antibody process development, commercial manufacturing, and global project management from his time at Novo Nordisk A/S, Maxigen, Inc., and Genmab A/S.
Vignesh Rajah, MBBS, DCH, MRCP(UK), MBA, serves as SVP, Chief Medical Officer. Dr Rajah qualified as physician in University of London, and has 10 years’ experience in hospital practice, specializing in Internal Medicine and Paediatric Critical Care in the UK.
Sue Smith serves as SVP, Chief Commercial Officer. Ms. Smith brings extensive commercial experience including from several successful product launches within cancer, rare diseases and endocrinology. Ms. Smith has more than 25 years of US and global oncology and rare disease experience.
Joris Wilms serves as SVP, Chief Operating Officer. Mr. Wilms has extensive industry experience in clinical development, with a focus in oncology and hematology indications. He has been responsible for overseeing several first-in-human studies and pivotal clinical trials, leading to the approval of
